Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefani Spranger

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Cell Reports|November 24, 2021
Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockadeChensu Wang, Ang Cui, Maurice Bukenya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Immunity|December 18, 2014
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumorsSeng-Ryong Woo, Mercedes B Fuertes, Leticia Corrales, et al.
JCI Insight|September 5, 2023
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2Brendan L Horton, Alicia D D'Souza, Maria Zagorulya, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Cancer Cell|December 15, 2012
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCLDaniel Nagel, Stefani Spranger, Michelle Vincendeau, et al.
Immunity|February 3, 2023
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancerMaria Zagorulya, Leon Yim, Duncan M Morgan, et al.
Molecular Cell|December 31, 2020
Increased demand for NAD<sup>+</sup> relative to ATP drives aerobic glycolysisAlba Luengo, Zhaoqi Li, Dan Y Gui, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustionTeresa Dinter, Sebastian Mackowiak, Zachary J Rogers, et al.
Science Advances|April 19, 2023
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulationSachin H Bhagchandani, Farrukh Vohidov, Lauren E Milling, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Cell Reports|November 24, 2021
Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockadeChensu Wang, Ang Cui, Maurice Bukenya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Immunity|December 18, 2014
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumorsSeng-Ryong Woo, Mercedes B Fuertes, Leticia Corrales, et al.
JCI Insight|September 5, 2023
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2Brendan L Horton, Alicia D D'Souza, Maria Zagorulya, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Cancer Cell|December 15, 2012
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCLDaniel Nagel, Stefani Spranger, Michelle Vincendeau, et al.
Immunity|February 3, 2023
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancerMaria Zagorulya, Leon Yim, Duncan M Morgan, et al.
Molecular Cell|December 31, 2020
Increased demand for NAD<sup>+</sup> relative to ATP drives aerobic glycolysisAlba Luengo, Zhaoqi Li, Dan Y Gui, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustionTeresa Dinter, Sebastian Mackowiak, Zachary J Rogers, et al.
Science Advances|April 19, 2023
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulationSachin H Bhagchandani, Farrukh Vohidov, Lauren E Milling, et al.
Pageof 9